Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension

Dr Neal Shore speaks to ecancer about the post hoc analysis of the phase three EMBARK trial.

This study evaluated whether patients with high-risk biochemical recurrence of prostate cancer could maintain disease control after stopping therapy.

The results showed that patients treated with enzalutamide plus leuprolide were more likely to sustain prostate-specific antigen levels below 0.2 nanograms per milliliter for up to three years after treatment suspension compared with either therapy alone.

Notably, about 1 in 25 patients receiving combination therapy maintained low prostate-specific antigen levels alongside recovery of normal testosterone levels, suggesting the possibility of durable treatment-free remission.

These findings highlight the long-term benefit of combination therapy over monotherapy approaches.